Published in J Clin Invest on September 09, 2013
Validation of a multiprotein plasma classifier to identify benign lung nodules. J Thorac Oncol (2015) 0.90
An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. Immunol Res (2014) 0.83
Oncogene withdrawal engages the immune system to induce sustained cancer regression. J Immunother Cancer (2014) 0.80
Photodynamic therapy-mediated cancer vaccination enhances stem-like phenotype and immune escape, which can be blocked by thrombospondin-1 signaling through CD47 receptor protein. J Biol Chem (2015) 0.78
Thrombospondin 1 Deficiency Ameliorates the Development of Adriamycin-Induced Proteinuric Kidney Disease. PLoS One (2016) 0.77
p53 Restoration in Induction and Maintenance of Senescence: Differential Effects in Premalignant and Malignant Tumor Cells. Mol Cell Biol (2015) 0.76
Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells. Oncotarget (2016) 0.75
Transcriptional and Post-Transcriptional Regulation of Thrombospondin-1 Expression: A Computational Model. PLoS Comput Biol (2017) 0.75
Thrombospondin-1 in a Murine Model of Colorectal Carcinogenesis. PLoS One (2015) 0.75
Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer. Oncogene (2015) 0.75
CXCL13 Promotes Proliferation of Mesangial Cells by Combination with CXCR5 in SLE. J Immunol Res (2016) 0.75
Thrombospondin expression in myofibers stabilizes muscle membranes. Elife (2016) 0.75
The Immortal Senescence. Methods Mol Biol (2017) 0.75
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell (1997) 29.13
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 16.87
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev (2001) 15.97
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem (1998) 13.93
Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods (2006) 12.63
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell (1997) 12.41
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell (2008) 9.22
Oncogene-induced senescence as an initial barrier in lymphoma development. Nature (2005) 9.16
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
Ras oncogenes: split personalities. Nat Rev Mol Cell Biol (2008) 7.91
Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol Cell Biol (1992) 7.72
Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell (2008) 7.65
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature (2001) 7.06
A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell (2006) 6.96
Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell (2008) 6.84
Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer (2004) 6.67
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14
Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol (2002) 6.05
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93
Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev (1998) 5.60
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (1994) 5.54
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 5.07
Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer (2009) 5.02
Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science (1997) 4.97
Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol (2007) 4.67
Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol (1997) 4.36
The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A (2005) 3.49
PML is induced by oncogenic ras and promotes premature senescence. Genes Dev (2000) 3.35
Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J (1999) 3.17
Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature (2010) 3.03
The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol (2008) 2.98
Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med (2002) 2.97
High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol (1997) 2.89
PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase. Dev Cell (2001) 2.73
Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol (2002) 2.61
Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature (2010) 2.51
Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. J Clin Invest (1998) 2.51
Many roads lead to oncogene-induced senescence. Oncogene (2008) 2.43
The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity. J Cell Sci (2005) 2.40
Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol (2008) 2.30
Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene (1999) 2.00
Functional coupling between the extracellular matrix and nuclear lamina by Wnt signaling in progeria. Dev Cell (2010) 1.90
Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc Natl Acad Sci U S A (2001) 1.79
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell (2008) 1.72
Murine nasal septa for respiratory epithelial air-liquid interface cultures. Biotechniques (2007) 1.59
Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res (2008) 1.58
Thrombospondin 1 accelerates synaptogenesis in hippocampal neurons through neuroligin 1. Nat Neurosci (2009) 1.42
Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol Cell Biol (2000) 1.41
The genetic basis of susceptibility to lung tumors in mice. Toxicology (1989) 1.34
Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation. J Exp Med (2003) 1.32
Protein-protein interactions in the regulation of the extracellular signal-regulated kinase. Mol Biotechnol (2005) 1.28
Murine tracheal and nasal septal epithelium for air-liquid interface cultures: a comparative study. Am J Rhinol (2007) 1.19
PEA-15 is inhibited by adenovirus E1A and plays a role in ERK nuclear export and Ras-induced senescence. J Biol Chem (2004) 1.15
Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen. Clin Cancer Res (2009) 1.14
Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer. Lung Cancer (2002) 1.04
Differences between adult and foetal fibroblasts in the regulation of hyaluronate synthesis: correlation with migratory activity. J Cell Sci (1989) 1.03
Role of cytosolic phospholipase A(2) in prostaglandin E(2) production by lung fibroblasts. Am J Respir Cell Mol Biol (2003) 1.01
Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. Clin Cancer Res (1999) 0.91
4F2 monoclonal antibody recognizes a surface antigen on spread human fibroblasts of embryonic but not of adult origin. J Cell Biol (1984) 0.88
Differential response of fetal and adult fibroblasts to cytokines: cell migration and hyaluronan synthesis. Development (1997) 0.87
Nicotine-induced morphological changes in rat aorta: the protective role of melatonin. Cells Tissues Organs (2011) 0.81
Loss of PPARγ expression by fibroblasts enhances dermal wound closure. Fibrogenesis Tissue Repair (2012) 0.77
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest (2007) 9.33
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 8.21
Modeling the therapeutic efficacy of p53 restoration in tumors. Cell (2006) 5.95
Modelling Myc inhibition as a cancer therapy. Nature (2008) 5.81
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell (2002) 5.29
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 5.16
Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol (2007) 4.65
Distinct thresholds govern Myc's biological output in vivo. Cancer Cell (2008) 4.16
A matter of life and death. Cancer Cell (2002) 4.07
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature (2009) 3.93
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40
Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood (2007) 3.38
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med (2007) 3.11
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivo. Nat Immunol (2011) 3.04
p53--a Jack of all trades but master of none. Nat Rev Cancer (2009) 2.96
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res (2010) 2.64
Characterization of the cell of origin for small cell lung cancer. Cell Cycle (2011) 2.62
Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature (2010) 2.51
Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell (2007) 2.42
A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci (2003) 2.34
Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell (2006) 2.32
Temporal dissection of p53 function in vitro and in vivo. Nat Genet (2005) 2.19
Endogenous Myc maintains the tumor microenvironment. Genes Dev (2011) 2.16
Tumor-associated neutrophils: friend or foe? Carcinogenesis (2012) 2.15
Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol (2012) 2.14
p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science (2009) 2.11
Lung stem cell self-renewal relies on BMI1-dependent control of expression at imprinted loci. Cell Stem Cell (2011) 2.09
TORC1 is essential for NF1-associated malignancies. Curr Biol (2007) 2.08
Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proc Natl Acad Sci U S A (2008) 1.90
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A (2006) 1.89
The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev (2006) 1.87
Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res (2005) 1.86
Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res (2009) 1.86
HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A (2010) 1.86
Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood (2011) 1.84
Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. Cell Stem Cell (2010) 1.81
Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood (2010) 1.81
MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst (2009) 1.80
A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res (2007) 1.78
PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Am J Physiol Lung Cell Mol Physiol (2003) 1.74
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell (2008) 1.72
Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One (2008) 1.72
Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol Cell (2012) 1.71
The ups and downs of Myc biology. Curr Opin Genet Dev (2009) 1.70
A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med (2013) 1.69
Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget (2012) 1.67
Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes (2007) 1.67
Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res (2008) 1.65
Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling. Cancer Biol Ther (2003) 1.65
Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis. Cancer Res (2006) 1.64
ANGPT2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio. Am J Respir Crit Care Med (2011) 1.62
The calcineurin-NFAT-angiopoietin-2 signaling axis in lung endothelium is critical for the establishment of lung metastases. Cell Rep (2013) 1.61
Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev (2013) 1.60
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res (2011) 1.53
Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol (2010) 1.51
Does mild cognitive impairment increase the risk of developing postoperative cognitive dysfunction? Am J Surg (2010) 1.51
Variation in the myosin light chain kinase gene is associated with development of acute lung injury after major trauma. Crit Care Med (2008) 1.50
Gene therapy for mesothelioma and lung cancer. Am J Respir Cell Mol Biol (2010) 1.49
CCL2 blockade augments cancer immunotherapy. Cancer Res (2009) 1.48
c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res (2004) 1.48
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther (2008) 1.47
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res (2007) 1.47
Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat Biotechnol (2003) 1.46
Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology (2005) 1.45
Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res (2006) 1.42
Gene expression profiling of the early pulmonary response to hyperoxia in mice. Am J Respir Cell Mol Biol (2003) 1.41
Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One (2012) 1.40
Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res (2006) 1.40
Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci U S A (2012) 1.40
Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol (2012) 1.39
Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat (2012) 1.39
Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res (2008) 1.38
Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest (2014) 1.33
PECAM-1 functions as a specific and potent inhibitor of mitochondrial-dependent apoptosis. Blood (2003) 1.33
Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer. PLoS One (2013) 1.32
Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia. Oncogene (2004) 1.32
Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res (2008) 1.32
Urinary volatile compounds as biomarkers for lung cancer: a proof of principle study using odor signatures in mouse models of lung cancer. PLoS One (2010) 1.31
Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood (2002) 1.30
Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J (2014) 1.30
ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood (2003) 1.28
Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res (2009) 1.27
Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung. Cancer Res (2005) 1.26